DATE

<<PATIENTFIRST>> <<PATIENTLAST>>

<<ADDRESS1>>

<<ADDRESS2>>

Dear << PATIENT NAME >>

**RE: Notice of IVIg Brand Switch**

There are ongoing world-wide challenges with the supply of intravenous immunoglobulin (IVIg), which are expected to continue until at least spring 2022. To ensure an ongoing supply of IVIg, Canadian Blood Services has recently made changes to the brands of IVIg that they carry.

You are one of many patients who receive <<INSERT BRAND NAME>> on a regular basis. You will need to be transitioned to a different IVIg brand by April 2021. The replacement brand of IVIg is expected to be as effective for you as the <<INSERT BRAND NAME>> has been. However, because side effects may vary across IVIg brands, the first time you receive the replacement brand of IVIg, the infusion rate will be slowed (given at the rate that would be used for a first-time patient) to watch for any side effects. This will mean that the time required to receive your first infusion of the replacement IVIg brand will be longer than you are used to.

The replacement brand of IVIg will be determined based on available IVIg inventory closer to your next infusion date.

Your prescribing physician and infusion clinic/site staff will be informed of this upcoming change. We kindly ask you to discuss the scheduling of your first infusion of the replacement brand of IVIg with the infusion clinic/site staff, to ensure that everyone involved is prepared for this change.

Please contact your prescribing physician with any questions or concerns.

Sincerely,

TRANSFUSION MEDICINE PHYSICIAN NAME & SIGNATURE

Cc: <<WARD – NAME OF OUTPATIENT INFUSION DEPARTMENT>>